28 March, 2025 – BOSTON, MA – Tulip Interfaces, a leader in frontline operations technology, and Sartorius, a global leader in biopharmaceutical manufacturing solutions, have entered into a strategic commercial agreement to accelerate digital transformation in biopharmaceutical production. This partnership enables Sartorius to deliver robust digital solutions powered by Tulip, which will enhance its production processes for customers.
Under the agreement, Sartorius will leverage Tulip’s Frontline Operations Platform to enhance its Biobrain automation platform with cutting-edge digital applications for the commissioning, operation, and maintenance of Sartorius equipment. This collaboration will support Sartorius customers in scaling their digital manufacturing capabilities, reducing process variability, and improving compliance with industry regulations.
“This partnership with Sartorius is a major milestone in our mission to bring no-code, connected frontline operations to the biopharma industry,” said Roey Merchez, Head of Ecosystem and GM EMEA at Tulip. “By combining Sartorius’ deep expertise in biopharmaceutical production with Tulip’s intuitive, composable platform, we are enabling customers to digitize their operations with unprecedented speed and flexibility. Together, we are driving innovation in the field of human-machine interface (HMI), offering a composable HMI that seamlessly integrates machine data with execution and production data to create more intelligent and responsive manufacturing environments.”
As part of the collaboration, Sartorius will offer Biobrain® Operate, powered by Tulip, a suite of digital applications specifically designed to enhance the commissioning and operation of Sartorius equipment. This integrated approach will empower customers with real-time data insights, automated workflows, and intuitive interfaces, leading to increased productivity and operational excellence.
Micahela Pischke, Head of Separations Division Technologies at Sartorius, said, “Digitalization is a key driver of efficiency in biopharmaceutical manufacturing, and our partnership with Tulip will allow us to provide customers with advanced digital solutions tailored to their specific needs. Tulip’s no-code technology aligns perfectly with our vision of enabling seamless, data-driven decision-making across the production floor.”
The agreement covers worldwide biopharmaceutical manufacturing markets, allowing Sartorius to resell Tulip’s solutions to its global customer base. Both companies will collaborate on joint go-to-market initiatives, including co-marketing efforts, joint events, and the integration of Tulip’s technology into Sartorius’ global demonstration centers.
The partnership underscores the growing demand for flexible, user-friendly digital solutions in biopharmaceutical manufacturing. By bringing together Tulip’s cutting-edge technology and Sartorius’ industry expertise, the collaboration will help manufacturers streamline operations, improve quality, and accelerate time to market.
For more information on Tulip Interfaces and Sartorius, visit www.tulip.co and www.sartorius.com.
About Tulip
Tulip, the leader in frontline operations, is helping companies around the world equip their workforce with AI-enabled, connected apps—leading to higher quality work, improved efficiency, and end-to-end traceability across operations. With Tulip’s cloud-based platform, those closest to operations can take advantage of composability and edge connectivity to digitally transform processes, guide operators, track production, and gain a real-time, holistic view of operations. A spinoff out of MIT, the company is headquartered in Boston, MA, with offices in Germany, Singapore, and Hungary. For more information about Tulip Interfaces, visit www.tulip.co.
Contact: press@tulip.co
A profile of Sartorius
Sartorius is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services Division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions Division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and sustainably. The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through the acquisition of complementary technologies. In 2024, the company generated sales revenue of around 3.4 billion euros. Around 13,500 employees are working for customers around the globe. www.sartorius.com.